吡侖帕奈治療兒童癲癇的中國專家共識_Journal of Epilepsy

Authors：

 中國抗癲癇協會創新與轉化專業委員會 , 中華醫學會兒科學分會神經學組

執筆（按單位拼音和姓氏筆畫排列，排名不分先后）季濤云、姜玉武（北京大學第一醫院），操德智（深圳市兒童醫院），陳旭勤（上海交通大學醫學院附屬兒童醫院），方方（首都醫科大學附屬北京兒童醫院），馮建華（浙江大學醫學院附屬第二醫院），高峰、繆靜（浙江大學醫學院附屬兒童醫院），高麗（河南省人民醫院），黃紹平（西安交通大學第二附屬醫院），蔣莉（重慶醫科大學附屬兒童醫院），李霞（西安市兒童醫院），劉曉鳴（徐州市兒童醫院），劉雪雁（中國醫科大學附屬盛京醫院），劉占利（杭州市兒童醫院），羅蓉（四川大學華西第二醫院），梅道啟（蘇州大學附屬兒童醫院），彭鏡（中南大學湘雅醫院），孫丹（武漢兒童醫院），孫素真（河北省兒童醫院），王藝（復旦大學附屬兒科醫院），吳春風（南京市兒童醫院），張洪偉（山東大學附屬兒童醫院），張玉琴（天津市兒童醫院），禚志紅（鄭州大學第一附屬醫院）;

Corresponding?author：

中國抗癲癇協會創新與轉化專業委員會, Email: jiangyuwu@bjmu.edu.cn

Keywords：

DOI：

10.7507/2096-0247.202506002

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 中國抗癲癇協會創新與轉化專業委員會, 中華醫學會兒科學分會神經學組. 吡侖帕奈治療兒童癲癇的中國專家共識. Journal of Epilepsy, 2025, 11(4): 277-287. doi: 10.7507/2096-0247.202506002 Copy

1.	Yu PM, Ding D, Zhu GX, et al. International bureau for epilepsy survey of children, teenagers, and young people with epilepsy: data in China. Epilepsy Behav, 2009, 16(1): 99-104.
2.	陳耀龍, 楊克虎, 王小欽, 等. 中國制訂/修訂臨床診療指南的指導原則(2022版). 中華醫學雜志, 2022, 102(10): 697-703.
3.	American Academy of Neurology. Clinical practice guideline process manual, 2011 Ed. St. Paul, 2011.
4.	Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J ClinEpidemiol, 2011, 64(4): 401-406.
5.	Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: going from evidence to recommendation determinants of a recommendation's direction and strength. J Clin Epidemiol, 2013, 66(7): 726-735.
6.	中國抗癲癇協會. 臨床診療指南-癲癇病分冊(2023修訂版). 北京: 人民衛生出版社, 2023.
7.	Beniczky S, Trinka E, Wirrell E, et al. Updated classification of epileptic seizures: position paper of the International League Against Epilepsy. Epilepsia, 2025, 00: 1-20. Online ahead of print.
8.	Potschka H, Trinka E. Perampanel: does it have broad-spectrum potential? Epilepsia, 2019, 60(Suppl 1): 22-36.
9.	Perversi F, Costa C, Labate A, et al. The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy. Front Neurol, 2023, 14: 1182304.
10.	Wang T, Li L, Sun F, et al. Efficacy and safety of perampanel for the treatment of epilepsy in adolescents: a meta-analysis. Int J Neurosci, 2023, 133(9): 1008-1016.
11.	Flamini R, Fogarasi A, Omatsu H, et al. Long-term safety and efficacy of adjunctive perampanel in pediatric patients (ages 4 to <12 years) with inadequately controlled focal-onset seizures or generalized tonic-clonic seizures. Epilepsia, 2025, 66(4): 1097-1109.
12.	Ji TY, Ding YF, Zhang YQ, et al. Investigation of efficacy, safety and tolerability of perampanel monotherapy in children with newly-diagnosed epilepsy in routine clinical practice in China: a multicenter prospective observational study. World J Pediatr, 2025. Online ahead of print.
13.	Trinka E, Lattanzi S, Carpenter K, et al. Exploring the evidence for broad-spectrum effectiveness of perampanel: a systematic review of clinical data in generalized seizures. CNS Drugs, 2021, 35(8): 821-837.
14.	Fan PF, Zhuo C, Huang M. Efficacy and safety of perampanel for epilepsy: a systematic review and meta-analysis of real-world studies. Eur Rev Med Pharmacol Sci, 2023, 27(13): 6027-6039.
15.	Toledano Delgado R, García-Morales I, Parejo-Carbonell B, et al. Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: experience from a national multicenter registry. Epilepsia, 2020, 61(6): 1109-1119.
16.	Fujimoto A, Enoki H, Hatano K, et al. Replacement of valproic acid with new anti-seizure medications in idiopathic generalized epilepsy. J Clin Med, 2022, 11(15): 4582.
17.	Mir A, Alghamdi A, Alotaibi W, et al. A systematic review of the efficacy of perampanel as treatment for myoclonic seizures and symptomatic myoclonus. Epileptic Disord, 2022, 24(4): 633-646.
18.	Wang XH, Ji TY, Liu MM, et al. Effectiveness and safety of perampanel for pediatric patients with epilepsy: a real-world study from China. Pediatric Investigation, 2025, 00: 1-9. Online ahead of print.
19.	馬湖萍, 任蓉, 侯梅, 等. 新型抗癲癇發作藥物吡侖帕奈添加治療0~18歲兒童難治性癲癇的臨床觀察研究. 中國全科醫學, 2025, 28(2): 250-256.
20.	Qu R, Dai Y, Chen X, et al. Effectiveness and safety of perampanel in Chinese paediatric patients (2-14 years) with refractory epilepsy: a retrospective, observational study. Epileptic Disord, 2021, 23(6): 854-864.
21.	Chang FM, Fan PC, Weng WC, et al. The ef?cacy of perampanel in young children with drugresistant epilepsy. Seizure, 2020, 75: 82-86.
22.	張捷, 謝涵, 鄧泂, 等. 基于隨訪 6 個月療效結局的加用吡侖帕奈治療兒童藥物難治性癲的單中心前瞻性隊列研究. 中國循證兒科雜志, 2021, 16(4): 269-274.
23.	Alyazidi AS, Muthaffar OY, Bamaga AK, et al. The therapeutic role of perampanel in treating pediatric patients with dravet syndrome: a scoping review. Cureus, 2024, 16(7): e65017.
24.	中國抗癲癇協會創新與轉化專業委員會, 中華醫學會兒科學分會罕見病學組, 中華醫學會兒科學分會神經學組. Dravet 綜合征診斷與治療的中國專家共識. 癲癇雜志, 2024, 10(1): 1-11.
25.	Nissenkorn A, Kluger G, Schubert-Bast S, et al. Perampanel as precision therapy in rare genetic epilepsies. Epilepsia, 2023, 64(4): 866-74.
26.	Muthaffar OY, Bamaga AK, Alyazidi AS, et al. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome. Transl Pediatr, 2024, 13(4): 584-595.
27.	Yoshitomi S, Takahashi Y, Yamaguchi T, et al. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome. Epilepsy Res, 2019, 154: 34-38.
28.	Lin KL, Lin JJ, Chou ML, et al. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics. Epilepsy Behav, 2018, 85: 188-94.
29.	Qu R, Dai Y, Qu X, et al. Use of perampanel in children with refractory epilepsy of genetic aetiology. Epileptic Disord, 2022, 24(4): 687-695.
30.	Miao P, Zhu X, Jin W, et al. Efficacy of perampanel in pediatric epilepsy with known and presumed genetic etiology. Ann Clin Transl Neurol, 2023, 10(8): 1374-1382.
31.	中國抗癲癇協會創新與轉化專委會. Lennox-Gastaut 綜合征診斷治療的中國專家共識. 癲癇雜志, 2022, 8(3): 187-195.
32.	Vossler DG, Porter BE, Kira R, et al. Efficacy and safety of perampanel in patients with seizures associated with Lennox-Gastaut syndrome: a randomized tria l. Epilepsia, 2025, 66(2): 379-393.
33.	Auvin S, Dozieres B, Ilea A, et al. Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome. Epilepsy Behav, 2017, 74: 59-63.
34.	Matricardi S, Cesaroni E, Bonanni P, et al. Long-term effectiveness of add-on perampanel in patients with Lennox-Gastaut syndrome: A multicenter retrospective study. Epilepsia, 2023, 64(6): e98-e104.
35.	Alonso-Singer P, Aguilar-Amat Prior MJ, Oliva-Navarro J, et al. Perampanel as adjuvant treatment in epileptic encephalopathies: a multicenter study in routine clinical practice. Epilepsy Behav, 2022, 134: 108836.
36.	Matsuura R, Hamano SI, Ikemoto S, et al. Adjunctive perampanel therapy for patients with epileptic spasms. Pediatr Int, 2022, 64(1): e15364.
37.	Li X, Gao K, Li Y, et al. Effective treatment of NR2F1-related epilepsy with perampanel. Acta Epileptologica, 2024, 6(1): 3.
38.	Sanlidag B, K?ken ?Y, Temel Eü, et al. Benign epilepsy with centrotemporal spikes: is there a thalamocortical network dysfunction present? Seizure, 2020, 79: 44-48.
39.	Yue X, Liu XM, Chen J, et al. The efficacy and cognitive impact of perampanel monotherapy in patients with self-limited epilepsy with centrotemporal spikes: a retrospective analysis. Neuropsychiatr Dis Treat, 2023, 19: 1263-1271.
40.	岳璇, 劉曉鳴, 陳嬌, 等. 吡侖帕奈單藥治療伴中央顳區棘波的自限性癲癇療效觀察及安全性研究. 癲癇雜志, 2023, 9(5): 388-392.
41.	閆婷, 杜麗君, 李曉媛, 等. 吡侖帕奈單藥和添加治療兒童癲癇伴睡眠中癲癇性電持續狀態的療效及安全性研究. 實用藥物與臨床, 2024, 27(9): 668-672.
42.	Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. Epilepsia, 2022, 63(6): 1475-1499.
43.	Brandt C, Wechsler RT, O'Brien TJ, et al. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy. Seizure, 2020, 80: 115-123.
44.	Villanueva V, Montoya J, Castillo A, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study. Epilepsia, 2018, 59(9): 1740-1752.
45.	Operto FF, Orsini A, Sica G, et al. Perampanel and childhood absence epilepsy: a real life experience. Front Neurol, 2022, 13: 952900.
46.	Montoya Gutiérrez FJ, Díaz Román M, Cerveró Albert D. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment. Epilepsy Res, 2020, 165: 106378.
47.	Singh K, Shah YD, Luciano D, et al. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Epilepsy Behav, 2016, 61: 41-45.
48.	Mai J, Li H, He Y, et al. Efficacy and safety of perampanel as the first add-on therapy for children with epilepsy: A real-world multicenter prospective observational study. Seizure, 2024, 117: 44-49.
49.	易珈沁, 孫丹. 吡侖帕奈添加治療兒童癲癇療效及安全性: 一項單中心回顧性觀察性研究. 中國實用兒科雜志, 2024, 39(10): 779-784.
50.	Lim GY, Chen CL, Chan Wei Shih D. Utility and safety of perampanel in pediatric FIRES and other drug-resistant epilepsies. Child Neurol Open, 2021, 8: 2329048X211055335.
51.	Sokka A, Olsen P, Kirjavainen J, et al. Etiology, syndrome diagnosis, and cognition in childhood‐onset epilepsy: a population‐based study. Epilepsia Open, 2017, 2(1): 76-83.
52.	Shellhaas RA, Wusthoff CJ, Tsuchida TN, et al. Profile of neonatal epilepsies: characteristics of a prospective US cohort. Neurology, 2017, 89(9): 893-899.
53.	Bosch DG, Boonstra FN, Gonzaga-Jauregui C, et al. NR2F1 mutations cause optic atrophy with intellectual disability. Am J Hum Genet, 2014, 94(2): 303-309.
54.	Chen CA, Bosch DG, Cho MT, et al. The expanding clinical phenotype of Bosch-Boonstra-Schaaf optic atrophy syndrome: 20 new cases and possible genotype-phenotype correlations. Genet Med, 2016, 18(11): 1143-1150.
55.	Wang T, Wang J, Dou Y, et al. Clinical characteristics and prognosis in a large paediatric cohort with status epilepticus. Seizure, 2020, 80: 5-11.
56.	兒童癲癇持續狀態協作組. 兒童癲癇持續狀態診斷治療的中國專家共識(2022). 癲癇雜志, 2022, 8(5): 383-389.
57.	Perez DQ, Espiritu AI, Jamora RDG. Perampanel in achieving status epilepticus cessation: a systematic review. Epilepsy Behav, 2022, 128: 108583.
58.	Wachiropathum P, Nabangchang C, Likasitthananon N, et al. Efficacy of oral perampanel in status epilepticus and acute repetitive seizures in children at a tertiary care hospital in Thailand. Epilepsy Behav, 2021, 118: 107964.
59.	關月, 張筱芳, 牟菲, 等. 新型抗癲癇藥吡侖帕奈治療兒童癲癇持續狀態4例并文獻復習. 中國醫院藥學雜志, 2021, 41(16): 1680-1682.
60.	Nobili L, Beniczky S, Eriksson SH, et al. Expert opinion: managing sleep disturbances in people with epilepsy. Epilepsy Behav, 2021, 124: 108341.
61.	Xu S, Xu ZY, Zheng Y, et al. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures: A real-world experience in eastern China. Seizure, 2023, 110: 231-237.
62.	Wang Q, Xu Y, Chen Y, et al. Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study. Epilepsy Behav, 2022, 136: 108937.
63.	Kanemura H, Sano F, Hoshino H, et al. Efficacy of perampanel in epilepsy patients with autism spectrum disorder. Epilepsy Res, 2021, 170: 106550.
64.	Gupta S, Hwang Y, Ludwig N, et al. Case report: Off-label use of low-dose perampanel in a 25-month-old girl with a pathogenic SYNGAP1 variant. Front Neurol, 2023, 14: 1221161.
65.	Scorrano G, Lattanzi S, Salpietro V, et al. The cognitive and behavioural effects of perampanel in children with neurodevelopmental disorders: a systematic review. J Clin Med, 2024, 13(2): 372.
66.	Witt JA, Helmstaedter C. The impact of perampanel on cognition: a systematic review of studies employing standardized tests in patients with epilepsy. Seizure, 2022, 94: 107-111.
67.	Snoeijen-Schouwenaars FM, van Ool JS, Tan IY, et al. Evaluation of perampanel in patients with intellectual disability and epilepsy. Epilepsy Behav, 2017, 66: 64-67.
68.	Coombs ID, Ziobro J, Krotov V, et al. A gain-of-function GRIA2 variant associated with neurodevelopmental delay and seizures: functional characterization and targeted treatmen. Epilepsia, 2022, 63(12): e156-e163.
69.	吳曄, 操德智, 馮建華, 等. 兒童癲癇患者中吡侖帕奈使用的專家建議. 癲癇雜志, 2022, 8(2): 95-4576.
70.	Lee WT, Chan DWS, Gulati S, et al. Role of perampanel in the management of pediatric epilepsies in Asia: expert opinion. Pediatr Neurol, 2024, 151: 5-16.
71.	Lavu A, Aboulatta L, Abou-Setta AM, et al. Efficacy and safety of perampanel in epilepsy: a systematic review and meta-analysis of randomised controlled trials. Seizure, 2022, 102: 54-60.
72.	Sun S, Li X, Liu X. E?cacy, tolerability and safety of perampanel in children and adolescents with epilepsy: Systematic review and meta-analysis. Brain Dev, 2023, 45(5): 260-269.
73.	Chu H, Zhang X, Shi J, et al. Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis. J Neurol, 2023, 270(10): 4713-4728.
74.	Ikemoto S, Hamano S, Hirata Y, et al. Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years. Seizure, 2019, 73: 75-78.
75.	Chung S, Williams B, Dobrinsky C, et al. Perampanel with concomitant levetiracetam and topiramate: Post hoc analysis of adverse events related to hostility and aggression. Epilepsy Behav, 2017, 75: 79-85.
76.	Hsu WW, Sing CW, He Y, et al. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs, 2013, 27(10): 817-827.
77.	Hou LY, Yang JJ, Zhang X, et al. Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: a systematic review and meta-analysis. Front Pharmacol, 2023, 14: 1139514.
78.	Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol, 2016, 12(2): 106-116.
79.	Kanemura H, Sano F, Aihara M. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy. Eur J Paediatr Neurol, 2019, 23(1): 197-203.
80.	Eisai Co. , Ltd (per FDA). Perampanel label. 2023.
81.	Li S, Yi J, Tuo Y, et al. Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: a real-world study. Epilepsia, 2024, 65(6): 1687-1697.
82.	Renfroe JB, Mintz M, Davis R, et al. Adjunctive perampanel oral suspension in pediatric patients from ≥2 to <12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and ef?cacy. J Child Neurol, 2019, 34(5): 284-294.
83.	Wang H, Wang J, Lin B, et al. Effect of Age, Comedications, and CYP3A4/5 polymorphisms on perampanel exposure in Chinese pediatric patients with epilepsy. J Clin Pharmacol, 2024, 64(6): 737-743.
84.	Li Y, Dong N, Qin YX, et al. Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration-to-dose ratio. Epilepsia Open, 2022, 7(4): 737-746.
85.	Zhao T, Li HJ, Zhang HL, et al. Effects of CYP3A4 genetic polymorphisms on the pharmacokinetics and efficacy of perampanel in Chinese pediatric patients with epilepsy. Seizure, 2024, 120: 142-149.
86.	Zhao T, Feng JR, Zhang HL, et al. Effects of CYP3A5*3 genetic polymorphisms on the pharmacokinetics of perampanel in Chinese pediatric patients with epilepsy. Pharmacogenet Genomics, 2024, 34(6): 184-190.
87.	Yamamoto Y, Shiratani Y, Asai S, et al. Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy. Seizure, 2020, 83: 181-186.
88.	Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia, 2015, 56(1): 12-27.
89.	Yamamoto Y, Usui N, Nishida T, et al. Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs. Therapeutic Drug Monitoring, 2017, 39(4): 446-449.
90.	Ishikawa N, Tateishi Y, Tani H, et al. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy. Epilepsy Behav, 2019, 94: 82-86.
91.	Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 2008, 49(7): 1239-1276.

1. Yu PM, Ding D, Zhu GX, et al. International bureau for epilepsy survey of children, teenagers, and young people with epilepsy: data in China. Epilepsy Behav, 2009, 16(1): 99-104.
2. 陳耀龍, 楊克虎, 王小欽, 等. 中國制訂/修訂臨床診療指南的指導原則(2022版). 中華醫學雜志, 2022, 102(10): 697-703.
3. American Academy of Neurology. Clinical practice guideline process manual, 2011 Ed. St. Paul, 2011.
4. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J ClinEpidemiol, 2011, 64(4): 401-406.
5. Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: going from evidence to recommendation determinants of a recommendation's direction and strength. J Clin Epidemiol, 2013, 66(7): 726-735.
6. 中國抗癲癇協會. 臨床診療指南-癲癇病分冊(2023修訂版). 北京: 人民衛生出版社, 2023.
7. Beniczky S, Trinka E, Wirrell E, et al. Updated classification of epileptic seizures: position paper of the International League Against Epilepsy. Epilepsia, 2025, 00: 1-20. Online ahead of print.
8. Potschka H, Trinka E. Perampanel: does it have broad-spectrum potential? Epilepsia, 2019, 60(Suppl 1): 22-36.
9. Perversi F, Costa C, Labate A, et al. The broad-spectrum activity of perampanel: state of the art and future perspective of AMPA antagonism beyond epilepsy. Front Neurol, 2023, 14: 1182304.
10. Wang T, Li L, Sun F, et al. Efficacy and safety of perampanel for the treatment of epilepsy in adolescents: a meta-analysis. Int J Neurosci, 2023, 133(9): 1008-1016.
11. Flamini R, Fogarasi A, Omatsu H, et al. Long-term safety and efficacy of adjunctive perampanel in pediatric patients (ages 4 to <12 years) with inadequately controlled focal-onset seizures or generalized tonic-clonic seizures. Epilepsia, 2025, 66(4): 1097-1109.
12. Ji TY, Ding YF, Zhang YQ, et al. Investigation of efficacy, safety and tolerability of perampanel monotherapy in children with newly-diagnosed epilepsy in routine clinical practice in China: a multicenter prospective observational study. World J Pediatr, 2025. Online ahead of print.
13. Trinka E, Lattanzi S, Carpenter K, et al. Exploring the evidence for broad-spectrum effectiveness of perampanel: a systematic review of clinical data in generalized seizures. CNS Drugs, 2021, 35(8): 821-837.
14. Fan PF, Zhuo C, Huang M. Efficacy and safety of perampanel for epilepsy: a systematic review and meta-analysis of real-world studies. Eur Rev Med Pharmacol Sci, 2023, 27(13): 6027-6039.
15. Toledano Delgado R, García-Morales I, Parejo-Carbonell B, et al. Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: experience from a national multicenter registry. Epilepsia, 2020, 61(6): 1109-1119.
16. Fujimoto A, Enoki H, Hatano K, et al. Replacement of valproic acid with new anti-seizure medications in idiopathic generalized epilepsy. J Clin Med, 2022, 11(15): 4582.
17. Mir A, Alghamdi A, Alotaibi W, et al. A systematic review of the efficacy of perampanel as treatment for myoclonic seizures and symptomatic myoclonus. Epileptic Disord, 2022, 24(4): 633-646.
18. Wang XH, Ji TY, Liu MM, et al. Effectiveness and safety of perampanel for pediatric patients with epilepsy: a real-world study from China. Pediatric Investigation, 2025, 00: 1-9. Online ahead of print.
19. 馬湖萍, 任蓉, 侯梅, 等. 新型抗癲癇發作藥物吡侖帕奈添加治療0~18歲兒童難治性癲癇的臨床觀察研究. 中國全科醫學, 2025, 28(2): 250-256.
20. Qu R, Dai Y, Chen X, et al. Effectiveness and safety of perampanel in Chinese paediatric patients (2-14 years) with refractory epilepsy: a retrospective, observational study. Epileptic Disord, 2021, 23(6): 854-864.
21. Chang FM, Fan PC, Weng WC, et al. The ef?cacy of perampanel in young children with drugresistant epilepsy. Seizure, 2020, 75: 82-86.
22. 張捷, 謝涵, 鄧泂, 等. 基于隨訪 6 個月療效結局的加用吡侖帕奈治療兒童藥物難治性癲的單中心前瞻性隊列研究. 中國循證兒科雜志, 2021, 16(4): 269-274.
23. Alyazidi AS, Muthaffar OY, Bamaga AK, et al. The therapeutic role of perampanel in treating pediatric patients with dravet syndrome: a scoping review. Cureus, 2024, 16(7): e65017.
24. 中國抗癲癇協會創新與轉化專業委員會, 中華醫學會兒科學分會罕見病學組, 中華醫學會兒科學分會神經學組. Dravet 綜合征診斷與治療的中國專家共識. 癲癇雜志, 2024, 10(1): 1-11.
25. Nissenkorn A, Kluger G, Schubert-Bast S, et al. Perampanel as precision therapy in rare genetic epilepsies. Epilepsia, 2023, 64(4): 866-74.
26. Muthaffar OY, Bamaga AK, Alyazidi AS, et al. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome. Transl Pediatr, 2024, 13(4): 584-595.
27. Yoshitomi S, Takahashi Y, Yamaguchi T, et al. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome. Epilepsy Res, 2019, 154: 34-38.
28. Lin KL, Lin JJ, Chou ML, et al. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics. Epilepsy Behav, 2018, 85: 188-94.
29. Qu R, Dai Y, Qu X, et al. Use of perampanel in children with refractory epilepsy of genetic aetiology. Epileptic Disord, 2022, 24(4): 687-695.
30. Miao P, Zhu X, Jin W, et al. Efficacy of perampanel in pediatric epilepsy with known and presumed genetic etiology. Ann Clin Transl Neurol, 2023, 10(8): 1374-1382.
31. 中國抗癲癇協會創新與轉化專委會. Lennox-Gastaut 綜合征診斷治療的中國專家共識. 癲癇雜志, 2022, 8(3): 187-195.
32. Vossler DG, Porter BE, Kira R, et al. Efficacy and safety of perampanel in patients with seizures associated with Lennox-Gastaut syndrome: a randomized tria l. Epilepsia, 2025, 66(2): 379-393.
33. Auvin S, Dozieres B, Ilea A, et al. Use of perampanel in children and adolescents with Lennox-Gastaut Syndrome. Epilepsy Behav, 2017, 74: 59-63.
34. Matricardi S, Cesaroni E, Bonanni P, et al. Long-term effectiveness of add-on perampanel in patients with Lennox-Gastaut syndrome: A multicenter retrospective study. Epilepsia, 2023, 64(6): e98-e104.
35. Alonso-Singer P, Aguilar-Amat Prior MJ, Oliva-Navarro J, et al. Perampanel as adjuvant treatment in epileptic encephalopathies: a multicenter study in routine clinical practice. Epilepsy Behav, 2022, 134: 108836.
36. Matsuura R, Hamano SI, Ikemoto S, et al. Adjunctive perampanel therapy for patients with epileptic spasms. Pediatr Int, 2022, 64(1): e15364.
37. Li X, Gao K, Li Y, et al. Effective treatment of NR2F1-related epilepsy with perampanel. Acta Epileptologica, 2024, 6(1): 3.
38. Sanlidag B, K?ken ?Y, Temel Eü, et al. Benign epilepsy with centrotemporal spikes: is there a thalamocortical network dysfunction present? Seizure, 2020, 79: 44-48.
39. Yue X, Liu XM, Chen J, et al. The efficacy and cognitive impact of perampanel monotherapy in patients with self-limited epilepsy with centrotemporal spikes: a retrospective analysis. Neuropsychiatr Dis Treat, 2023, 19: 1263-1271.
40. 岳璇, 劉曉鳴, 陳嬌, 等. 吡侖帕奈單藥治療伴中央顳區棘波的自限性癲癇療效觀察及安全性研究. 癲癇雜志, 2023, 9(5): 388-392.
41. 閆婷, 杜麗君, 李曉媛, 等. 吡侖帕奈單藥和添加治療兒童癲癇伴睡眠中癲癇性電持續狀態的療效及安全性研究. 實用藥物與臨床, 2024, 27(9): 668-672.
42. Hirsch E, French J, Scheffer IE, et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. Epilepsia, 2022, 63(6): 1475-1499.
43. Brandt C, Wechsler RT, O'Brien TJ, et al. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy. Seizure, 2020, 80: 115-123.
44. Villanueva V, Montoya J, Castillo A, et al. Perampanel in routine clinical use in idiopathic generalized epilepsy: the 12-month GENERAL study. Epilepsia, 2018, 59(9): 1740-1752.
45. Operto FF, Orsini A, Sica G, et al. Perampanel and childhood absence epilepsy: a real life experience. Front Neurol, 2022, 13: 952900.
46. Montoya Gutiérrez FJ, Díaz Román M, Cerveró Albert D. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment. Epilepsy Res, 2020, 165: 106378.
47. Singh K, Shah YD, Luciano D, et al. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Epilepsy Behav, 2016, 61: 41-45.
48. Mai J, Li H, He Y, et al. Efficacy and safety of perampanel as the first add-on therapy for children with epilepsy: A real-world multicenter prospective observational study. Seizure, 2024, 117: 44-49.
49. 易珈沁, 孫丹. 吡侖帕奈添加治療兒童癲癇療效及安全性: 一項單中心回顧性觀察性研究. 中國實用兒科雜志, 2024, 39(10): 779-784.
50. Lim GY, Chen CL, Chan Wei Shih D. Utility and safety of perampanel in pediatric FIRES and other drug-resistant epilepsies. Child Neurol Open, 2021, 8: 2329048X211055335.
51. Sokka A, Olsen P, Kirjavainen J, et al. Etiology, syndrome diagnosis, and cognition in childhood‐onset epilepsy: a population‐based study. Epilepsia Open, 2017, 2(1): 76-83.
52. Shellhaas RA, Wusthoff CJ, Tsuchida TN, et al. Profile of neonatal epilepsies: characteristics of a prospective US cohort. Neurology, 2017, 89(9): 893-899.
53. Bosch DG, Boonstra FN, Gonzaga-Jauregui C, et al. NR2F1 mutations cause optic atrophy with intellectual disability. Am J Hum Genet, 2014, 94(2): 303-309.
54. Chen CA, Bosch DG, Cho MT, et al. The expanding clinical phenotype of Bosch-Boonstra-Schaaf optic atrophy syndrome: 20 new cases and possible genotype-phenotype correlations. Genet Med, 2016, 18(11): 1143-1150.
55. Wang T, Wang J, Dou Y, et al. Clinical characteristics and prognosis in a large paediatric cohort with status epilepticus. Seizure, 2020, 80: 5-11.
56. 兒童癲癇持續狀態協作組. 兒童癲癇持續狀態診斷治療的中國專家共識(2022). 癲癇雜志, 2022, 8(5): 383-389.
57. Perez DQ, Espiritu AI, Jamora RDG. Perampanel in achieving status epilepticus cessation: a systematic review. Epilepsy Behav, 2022, 128: 108583.
58. Wachiropathum P, Nabangchang C, Likasitthananon N, et al. Efficacy of oral perampanel in status epilepticus and acute repetitive seizures in children at a tertiary care hospital in Thailand. Epilepsy Behav, 2021, 118: 107964.
59. 關月, 張筱芳, 牟菲, 等. 新型抗癲癇藥吡侖帕奈治療兒童癲癇持續狀態4例并文獻復習. 中國醫院藥學雜志, 2021, 41(16): 1680-1682.
60. Nobili L, Beniczky S, Eriksson SH, et al. Expert opinion: managing sleep disturbances in people with epilepsy. Epilepsy Behav, 2021, 124: 108341.
61. Xu S, Xu ZY, Zheng Y, et al. Efficacy and safety of perampanel monotherapy in patients with focal-onset seizures: A real-world experience in eastern China. Seizure, 2023, 110: 231-237.
62. Wang Q, Xu Y, Chen Y, et al. Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study. Epilepsy Behav, 2022, 136: 108937.
63. Kanemura H, Sano F, Hoshino H, et al. Efficacy of perampanel in epilepsy patients with autism spectrum disorder. Epilepsy Res, 2021, 170: 106550.
64. Gupta S, Hwang Y, Ludwig N, et al. Case report: Off-label use of low-dose perampanel in a 25-month-old girl with a pathogenic SYNGAP1 variant. Front Neurol, 2023, 14: 1221161.
65. Scorrano G, Lattanzi S, Salpietro V, et al. The cognitive and behavioural effects of perampanel in children with neurodevelopmental disorders: a systematic review. J Clin Med, 2024, 13(2): 372.
66. Witt JA, Helmstaedter C. The impact of perampanel on cognition: a systematic review of studies employing standardized tests in patients with epilepsy. Seizure, 2022, 94: 107-111.
67. Snoeijen-Schouwenaars FM, van Ool JS, Tan IY, et al. Evaluation of perampanel in patients with intellectual disability and epilepsy. Epilepsy Behav, 2017, 66: 64-67.
68. Coombs ID, Ziobro J, Krotov V, et al. A gain-of-function GRIA2 variant associated with neurodevelopmental delay and seizures: functional characterization and targeted treatmen. Epilepsia, 2022, 63(12): e156-e163.
69. 吳曄, 操德智, 馮建華, 等. 兒童癲癇患者中吡侖帕奈使用的專家建議. 癲癇雜志, 2022, 8(2): 95-4576.
70. Lee WT, Chan DWS, Gulati S, et al. Role of perampanel in the management of pediatric epilepsies in Asia: expert opinion. Pediatr Neurol, 2024, 151: 5-16.
71. Lavu A, Aboulatta L, Abou-Setta AM, et al. Efficacy and safety of perampanel in epilepsy: a systematic review and meta-analysis of randomised controlled trials. Seizure, 2022, 102: 54-60.
72. Sun S, Li X, Liu X. E?cacy, tolerability and safety of perampanel in children and adolescents with epilepsy: Systematic review and meta-analysis. Brain Dev, 2023, 45(5): 260-269.
73. Chu H, Zhang X, Shi J, et al. Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis. J Neurol, 2023, 270(10): 4713-4728.
74. Ikemoto S, Hamano S, Hirata Y, et al. Efficacy and serum concentrations of perampanel for treatment of drug-resistant epilepsy in children, adolescents, and young adults: comparison of patients younger and older than 12 years. Seizure, 2019, 73: 75-78.
75. Chung S, Williams B, Dobrinsky C, et al. Perampanel with concomitant levetiracetam and topiramate: Post hoc analysis of adverse events related to hostility and aggression. Epilepsy Behav, 2017, 75: 79-85.
76. Hsu WW, Sing CW, He Y, et al. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs, 2013, 27(10): 817-827.
77. Hou LY, Yang JJ, Zhang X, et al. Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: a systematic review and meta-analysis. Front Pharmacol, 2023, 14: 1139514.
78. Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy. Nat Rev Neurol, 2016, 12(2): 106-116.
79. Kanemura H, Sano F, Aihara M. Usefulness of perampanel with concomitant levetiracetam for patients with drug-resistant epilepsy. Eur J Paediatr Neurol, 2019, 23(1): 197-203.
80. Eisai Co. , Ltd (per FDA). Perampanel label. 2023.
81. Li S, Yi J, Tuo Y, et al. Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: a real-world study. Epilepsia, 2024, 65(6): 1687-1697.
82. Renfroe JB, Mintz M, Davis R, et al. Adjunctive perampanel oral suspension in pediatric patients from ≥2 to <12 years of age with epilepsy: pharmacokinetics, safety, tolerability, and ef?cacy. J Child Neurol, 2019, 34(5): 284-294.
83. Wang H, Wang J, Lin B, et al. Effect of Age, Comedications, and CYP3A4/5 polymorphisms on perampanel exposure in Chinese pediatric patients with epilepsy. J Clin Pharmacol, 2024, 64(6): 737-743.
84. Li Y, Dong N, Qin YX, et al. Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration-to-dose ratio. Epilepsia Open, 2022, 7(4): 737-746.
85. Zhao T, Li HJ, Zhang HL, et al. Effects of CYP3A4 genetic polymorphisms on the pharmacokinetics and efficacy of perampanel in Chinese pediatric patients with epilepsy. Seizure, 2024, 120: 142-149.
86. Zhao T, Feng JR, Zhang HL, et al. Effects of CYP3A5*3 genetic polymorphisms on the pharmacokinetics of perampanel in Chinese pediatric patients with epilepsy. Pharmacogenet Genomics, 2024, 34(6): 184-190.
87. Yamamoto Y, Shiratani Y, Asai S, et al. Pharmacokinetics, tolerability, and clinical effectiveness of perampanel in Japanese patients with epilepsy. Seizure, 2020, 83: 181-186.
88. Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia, 2015, 56(1): 12-27.
89. Yamamoto Y, Usui N, Nishida T, et al. Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs. Therapeutic Drug Monitoring, 2017, 39(4): 446-449.
90. Ishikawa N, Tateishi Y, Tani H, et al. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy. Epilepsy Behav, 2019, 94: 82-86.
91. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 2008, 49(7): 1239-1276.

Previous Article
2025 年 4 期封面
Next Article
經皮耳迷走神經刺激治療成人癲癇及精神共患病的專家共識

Journal of Epilepsy

吡侖帕奈治療兒童癲癇的中國專家共識

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content